Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
The Team at Uptown Research Institute is excited to share the news about contributing to the success of the Phase 3 DT120 (lysergide) clinical research trial, led by Definium Therapeutics, Inc.
“Many patients with MDD aren't helped by existing treatments, often experiencing partial responses, frequent medication changes, and long-term side effects,” said John Sonnenberg, Ph.D., Emerge principal investigator, clinical psychologist, founder of Uptown Research Institute, and faculty member at Northwestern University Feinberg School of Medicine. "The Emerge topline results demonstrate that a single dose of DT120 ODT can produce a meaningful and durable benefit for people with depression. Importantly, these results stand apart from existing treatments, representing a potentially new paradigm for the management of major depression."
We want to thank every person involved on this trial, both staff and participants alike, as we continue to follow our mission of bringing science to practice.
You can read the full news article by clicking the link below: